# Poor sleep quality, insomnia, and short sleep duration before infection predict long-term symptoms after COVID-19

Federico Salfi <sup>1</sup> ,	Giulia Amicucci <sup>1,2</sup> , Domenico Corigliano <sup>1,2</sup> , Lorenzo Viselli <sup>1</sup> , Aurora
	D'Atri <sup>1</sup> , Daniela Tempesta <sup>1</sup> , and Michele Ferrara <sup>1*</sup>

<sup>1</sup>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy

<sup>2</sup>Department of Psychology, Sapienza University of Rome, Rome, Italy

\*Corresponding author

Prof. Michele Ferrara, Ph.D.

Department of Biotechnological and Applied Clinical Sciences

University of L'Aquila

Via Vetoio (Coppito 2)

67100 Coppito (AQ)

Italy

michele.ferrara@univag.it

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

**Abstract** 

Study objectives: Millions of COVID-19 survivors experience a wide range of long-term

symptoms after acute infection, giving rise to serious public health concerns. To date, few risk

factors for post-COVID-19 conditions have been determined. This study evaluated the role of

pre-infection sleep quality/duration and insomnia severity in the incidence of long-term

symptoms after COVID-19.

Methods: This prospective study involved two assessments (April 2020 and 2022). At

baseline, sleep quality/duration and insomnia symptoms in participants without current/prior

SARS-CoV-2 infection were measured using the Pittsburgh Sleep Quality Index (PSQI) and

the Insomnia Severity Index (ISI). At follow-up, we evaluated the presence of twenty-one

symptoms (psychiatric, neurological, cognitive, bodily, and respiratory) one month (n=713,

infection in April 2020–February 2022) and three months after COVID-19 (n=333, infection in

April 2020-December 2021). Zero-inflated negative binomial models were used to estimate

the effect of previous sleep on the number of long-term symptoms. Binomial logistic

regressions were performed to evaluate the association between sleep outcomes and the

incidence of each post-COVID-19 symptom.

Results: Analyses highlighted a significant effect of pre-infection sleep on the number of

symptoms one/three months after COVID-19. Previous higher PSQI and ISI scores, and

shorter sleep duration significantly increased the risk of almost every long-term symptom at

one/three months from COVID-19.

Conclusion: This study suggested a prospective dose-dependent association between pre-

infection sleep quality/quantity and insomnia severity with the manifestation of post-COVID-

19 symptoms. Promoting sleep health may represent an effective preventive approach to

mitigate the COVID-19 sequelae, with substantial public health and societal implications.

**Keywords** 

Insomnia, post-COVID-19 symptoms, prospective association, public health, sleep and

2

immunity.

# Statement of significance

Determining potential risk factors of long COVID is crucial to driving preventive interventions amongst vulnerable populations. The present study is the first to provide insights into the role of pre-infection sleep disturbances in the occurrence of post-COVID-19 conditions. We demonstrated a strong association between previous sleep quality/duration and insomnia severity with the incidence of a broad spectrum of long-term symptoms one and three months after COVID-19. These results may have large-scale implications, considering the alarming rates of both sleep disturbances and post-COVID-19 manifestations worldwide. Further research is warranted to determine the biobehavioral mechanisms involved. Future studies should also evaluate whether treating sleep problems may improve the subsequent long-term consequences of COVID-19.

Introduction

Estimates from the World Health Organization indicate that over 750 million Coronavirus

Disease 2019 (COVID-19) cases have been confirmed globally. While most individuals

experience mild symptoms and recover quickly, recent meta-analyses suggested that 43–45%

of COVID-19 survivors report signs and symptoms that continue or develop in the long run.<sup>2,3</sup>

This condition is commonly termed "long COVID" and encompasses over two-hundred long-

term clinical manifestations. 4 General symptoms include fatigue, body aches, fever, ageusia,

and anosmia. Other symptoms are related to lung disease (i.e., cough, dyspnea) or involve

neurological and cognitive dysfunctions (headache, brain fog, attention/concentration

disorders, memory loss) and cardiovascular or gastrointestinal disorders. Moreover, a broad

spectrum of psychiatric and psychological manifestations after acute infection were also

identified, such as sleep disorders, depression, anxiety, post-traumatic stress disorder

(PTSD), obsessive-compulsive disorders (OCD) and psychosis.<sup>5</sup> This disabling condition

pervasively impacts the daily life of COVID-19 survivors, also affecting their ability to resume

a regular working routine.6,7

Identifying potential antecedents of long-term symptoms represents a first-order medical

challenge due to the burden on the international healthcare systems and the societal and

economic costs.8 However, due to the multisystemic and heterogeneous nature of long

COVID, its etiology remains poorly understood, and current evidence propose chronic

inflammation and immune dysregulation as possible causes of long-term clinical

manifestations after acute illness.9-12

Sleep plays a crucial role in human immunity, 13,14 and poor sleep quality and inadequate sleep

duration are associated with increased susceptibility to virus infections. 15,16 Moreover, a

growing body of evidence linked sleep disturbances and short sleep duration with increased

risk for inflammatory diseases due to the relationship between sleep problems and low sleep

amount with sustained production of pro-inflammatory cytokines and other circulating markers

4

of inflammation. 17,18

Based on these assumptions, pre-infection sleep disturbances could play a role in predisposing people to experience long-term symptoms after COVID-19. However, to the best of our knowledge, no prospective studies have addressed this research question. In this study, sleep outcomes of validated questionnaires from a nationwide survey held during the first Italian lockdown (April 2020) were used as predictors of long COVID symptoms in a group who reported a positive swab for SARS-CoV-2 in the subsequent two years. We hypothesized that sleep disturbances and shorter sleep duration could be prospectively associated with the occurrence of a wide range of long-term symptoms after one and three months from COVID-19 while accounting for established risk factors (age, gender, body mass index – BMI, COVID-19 severity).<sup>2,19–21</sup> Finally, we investigated whether sleep issues before infection were related to longer recovery times to return to the pre-infection daily functioning level.

#### **Materials and methods**

## Participants and procedure

A total of 13,989 participants were surveyed during the first lockdown period in April 2020 via a web-based set of questionnaires (for a detailed description of the data collection procedure, see<sup>22</sup>). Subsequently, a total of 2,013 respondents were longitudinally evaluated in December 2020.<sup>23</sup> Finally, the overall sample surveyed in April 2020 was re-invited to take part in another longitudinal assessment in April 2022. A total of 2,759 Italians participated in the last data collection, while a total of 1,062 respondents participated in all three survey waves.<sup>24</sup> Each assessment comprised an evaluation of sleep quality/duration and insomnia severity using the Pittsburgh Sleep Quality Index<sup>25</sup> (PSQI), and the Insomnia Severity Index<sup>26</sup> (ISI).

The PSQI is a reliable questionnaire to evaluate sleep quality.<sup>25</sup> It consists of nineteen questions, from which a total score (range, 0-21) is calculated. A higher score indicates poorer sleep quality. The ISI is a validated screening instrument to assess the severity of insomnia symptoms.<sup>26</sup> It comprised seven items and a higher total score (range, 0–28) point to more severe insomnia.

5

Moreover, in each survey wave we collected demographic and other information (for more details, see<sup>22-24</sup>). In April 2022, we asked respondents if they have ever tested positive for COVID-19. If so, participants were asked to answer a set of ad hoc questions about their infection and symptomatology. We collected information about:

- I. the month of detected swab positivity;
- II. the COVID-19 severity in the acute stage of illness (no marked symptoms: absence of any symptom except for smell/taste dysfunctions; mild disease: e.g., cough, fever, muscle pains, etc., without pneumonia; moderate disease: non-severe pneumonia and having received different medications without the need of extra oxygen treatment; severe disease: severe pneumonia requiring extra-oxygen therapy and intravenous lines attached);
- III. the recovery time (in weeks) to return to the pre-infection daily functioning level;
- IV. the presence of long-term symptoms one and three months after the first infection according to Italian National Institute of Health guidelines for long-COVID identification (over-tiredness. muscle weakness. breathlessness/dyspnea, concentration/attention difficulty, headache, asthenia, anxiety, diffuse body pain, sleep problems, memory problems, brain fog, deterioration of perceived health status, persistent cough, smell/taste dysfunctions, depression, appetite reduction, fever, PTSD, cardiovascular problems, OCD, psychosis).

From the overall April 2022 sample, a total of 973 participants (35.00%, mean age ± standard deviation, 33.40 ± 11.40 years; range, 18-81 years; 170 males) reported SARS-CoV-2 infection and provided the above-listed information. The temporal distributions of COVID-19 cases across the pandemic period in our sample and among the over 18-year Italian population are reported in Figure 1.

To estimate the role of sleep quality, insomnia severity, and total sleep time (TST, extracted from the item 4 of PSQI) in predicting long-term symptoms one month from COVID-19, the analyses were performed on 713 people (33.38 ± 11.40 years; 18–81 years; 122 males) who reported the positivity from April 2020 to February 2022, excluding subjects whose infection

was less than a month old during the third survey wave or people already infected during the first survey wave. To evaluate the effect of sleep variables in predicting long-term symptoms at three months from the infection, the analyses were performed on 333 individuals (33.09 ± 11.80 years; 18-70 years; 60 males) who reported a swab positivity from February 2020 to December 2021, excluding subjects whose infection was less than three months old in April 2022 or people reporting infection before/during the first assessment (April 2020). The flow chart of participants analyzed in the study is reported in Figure S1 in the supplemental material.

The project was approved by the Institutional Review Board of the University of L'Aquila (protocol no. 43066). Respondents provided electronic consent to participate in the study in each survey wave.




Figure 1. Temporal distribution of COVID-19 cases among the over 18-year Italian population (weekly; dark blue line) and in the overall study sample (n= 973; monthly; light blue bars).

Statistical analysis

We planned three analysis families to evaluate the predictive effect of the sleep variables on

(i) the number of long-term symptoms, (ii) the odds of each long-term symptom, and (iii) the

odds of recovering the pre-infection daily functioning level in longer times (after 4 or 12 weeks).

All analyses described in the following sections were adjusted for demographic confounding

variables [age, gender, and BMI (weight/height<sup>2</sup>)]. All tests were two-tailed and a p-value <

0.05 was considered significant.

A set of control analyses were also performed to evaluate the consistency of our results.

Firstly, all analyses were further adjusted for the COVID-19 severity, considering the

established relationship between acute illness severity and future

symptoms.<sup>2,19,20,27</sup> Secondly, models were fitted including the number of months between April

2020 and the time of the infection as covariate to control for the time distance between actual

infection and the first survey wave. Finally, analyses were performed also using a different

baseline assessment of sleep variables (December 2020; see "Supplemental statistical

analysis" section in the supplemental material).

Analysis on the number of long-term symptoms after COVID-19

The numbers of symptoms at one/three months from COVID-19 were entered as dependent

variables (range, 0-21), and the sleep variables (PSQI score, ISI score, TST) as separate

predictors. Due to the nature of the dependent variables (count data), linear regressions are

unsuitable.<sup>28,29</sup> Therefore, we evaluated the possibility of performing Poisson regressions,

which are typically used to model count data.<sup>28,29</sup> However, preliminary analyses highlighted

a violation of the equidispersion assumption<sup>29</sup> ( $\chi^2/df$  ranging from 3.94 to 5.48, greater than

the acceptable value of 1.20<sup>30</sup>). In this case, a Negative Binomial (NB) regression approach

should be used.  $^{28,31,32}$  NB models provide estimates [exp(B)] that indicate the rate change of

8

the count variable for a one-unit change in the predictor.

Due to the high prevalence of zero values in count variables (27.9% and 52.6% in one-month

and three-month symptoms, respectively), data were modeled with Zero-Inflated NB

regression<sup>33–35</sup> (ZINB). The ZINB approach combines two separate models: a ZI model and a

NB model. The ZI portion is used to model the probability of a zero count, while the negative

binomial portion is used to model the count itself. The ZINB model is useful in analyzing count

data that has an excess of zero values because it accounts for this excess in the data and

provides more accurate estimates of the underlying distribution. Therefore, the ZINB models

allowed us to manage both the excess of zero observations and the overdispersion in the

data.

Six ZINB models (M) were tested, evaluating the effect of PSQI, ISI, and TST in predicting the

number of symptoms at one month (M1, M2, M3, respectively) and three months from infection

(M4, M5, M6, respectively). The models were fitted using "countereg" R package.<sup>36</sup> In the

results section, we focused on the NB portion of ZINB models for addressing the role of sleep

variables in predicting the number of long-term symptoms. A comparison of relative goodness-

of-fit (Akaike information criterion and the Bayesian information criterion) supported the use of

ZINB regressions instead of NB (see Table S1 in the supplemental material). Moreover, a

visual inspection of Tukey's rootograms<sup>37</sup> using the "countereg" R package<sup>38</sup> confirmed ZINB

as the best-fit models.

Analysis on each long-term symptom after COVID-19

Binomial logistic regressions were performed to evaluate the association between sleep

variables and the future occurrence of each long-term symptom one and three months after

COVID-19. Analyses were performed using "qlm" function of "stats" R package.<sup>39</sup> In detail,

each sleep variable was entered as a predictor (PSQI score, ISI score, TST), and each long-

term symptom as a dichotomous dependent variable (yes, no). The criterion of a minimum of

5 outcome events per predictor variable (EPV) was adopted 40 to identify the analyzable long-

term symptoms after infection. Consequently, some symptoms were excluded from the

9

analysis on one-month (psychosis and OCD) and three-month symptoms (PTSD, fever,

persistent cough, OCD, appetite reduction, cardiovascular problems, and psychosis) due to

insufficient events. Considering the relaxed EPV criterion adopted to maximize the number of

analyzable long-term symptoms, sensitivity analyses were performed replicating the binomial

logistic models using the Firth's bias reduction method.<sup>41</sup> This approach allows the parameter

estimations to be more efficient and robust to small sample sizes and rare events by penalizing

the likelihood function. These control analyses were applied using "logistf" R package. 42

Analysis on recovery time after COVID-19

Binomial logistic regressions were performed to test the association between sleep

characteristics (quality, duration, insomnia severity) and the recovery time to return to the pre-

infection daily functioning level. The self-reported recovery time was entered as dichotomous

dependent variable (≤ 4 weeks vs. > 4 weeks for the one-month symptoms sample; ≤ 12 weeks

vs. > 12 weeks for the three-month symptoms sample), while sleep variables (PSQI score, ISI

score, TST) were used as predictors.

Results

Sample characteristics and COVID-19-related information

The composition of the analyzed samples is reported in Table 1. Most participants were young,

females, fell within the healthy weight range, and had at least a bachelor's degree. The

majority of respondents reported a mild COVID-19 severity in the acute stage and recovered

the pre-infection daily functioning level in less than a month. Descriptive statistics of

questionnaire scores assessing sleep quality, severity of insomnia symptoms, and sleep

10


duration are also reported.

Table 1. Demographic characteristics, information about COVID-19, and descriptive statistics of questionnaire scores evaluating sleep quality, insomnia severity, and sleep duration among participants who were tested positive for SARS-CoV-2 from April 2020 to February 2022, and from April to December 2021.

Variable	COVID-19 in April 2020–February 2022 (n = 713)	COVID-19 in April 2020–December 2021 (n = 333)			
	N (%) or *mean (SD)				
Age					
Younger (18 to 30 years)	390 (54.7)	194 (58.3)			
Middle-aged (31 to 50 years)	250 (35.1)	100 (30.0)			
Older (> 50 years)	73 (10.2)	39 (11.7)			
Gender					
Male .	122 (17.1)	60 (18.0)			
Female	591 (82.9)	273 (82.0)			
BMI	40 (0.7)	00 (0.0)			
Underweight range (< 18.5)	48 (6.7)	23 (6.9)			
Healthy weight range (18.5 to < 25)  Overweight range (25 to < 30)	462 (64.8) 146 (20.5)	205 (61.6) 69 (20.7)			
Obesity (≥ 35)	57 (8.0)	36 (10.8)			
Education	37 (6.0)	30 (10.0)			
Middle/High school	216 (30.3)	106 (31.8)			
Bachelor's degree	171(24.0)	108 (32.4)			
Master's degree	229 (32.1)	78 (23.4)			
Postgraduate	97 (13.6)	41(12.3)			
COVID-19 severity	· ,	,			
No marked symptoms	183 (25.7)	84 (25.2)			
Mild disease	490 (68.7)	220 (66.1)			
Moderate disease	33 (4.6)	22 (6.6)			
Severe disease	7 (1.0)	7 (2.1)			
Time to recover the pre-infection daily fur					
≤ 4 weeks	479 (67.2)				
> 4 weeks	234 (32.8)	070 (04.4)			
≤ 12 weeks		270 (81.1)			
> 12 weeks	*6.050 : 2.575	63 (18.9)			
PSQI score ISI score	*6.950 ± 3.575 *8.279 ± 5.419	*6.885 ± 3.694 *8.171 ± 5.330			
Sleep duration (hour)	*7.205 ± 1.358	*7.215 ± 1.422			
Sieep duration (nour)	1.200 ± 1.300	1.210 ± 1.422			

Notes: Numbers preceded by an asterisk (\*) are mean values (standard deviation). BMI ranges were established according to the American Centers for Disease Control and Prevention guidelines. 43 Abbreviations: BMI, Body mass index; ISI, Insomnia Severity Index; PSQI, Pittsburgh Sleep Quality Index; SD, Standard deviation.

The prevalence of each long-term symptom one month and three months after COVID-19 among the analyzed samples is reported in Figure 2a. The distribution of the number of symptoms at one month and three months from the infection is shown in Figure 2b.






Figure 2. Prevalence of long-term symptoms (a) and distribution of symptoms number (b) one month and three months after COVID-19 in the analyzed samples.

Notes: The "After 1 month" group consists of 713 individuals (dark blue bars), while the "After 3 months" group comprises 333 subjects (light blue bars).

Abbreviations: OCD, obsessive-compulsive disorder; PTSD, post-traumatic stress disorder.

Association between pre-infection sleep and the number of long-term

symptoms after COVID-19

Results from the NB portion of the ZINB models (Table 2) showed that lower sleep quality,

more severe insomnia symptoms, and shorter sleep duration significantly predicted a higher

number of long-term symptoms at one month and three months after COVID-19. A one-unit

increase in PSQI and ISI scores, and a one-hour reduction of sleep duration predicted a 7.0%,

4.9%, and 11.1% increase in the number of symptoms one month after infection, and an

increase of 9.1%, 5.4%, and 14.7% in the number of symptoms three months after COVID-

19, respectively. A graphical representation of the relationships between sleep variables and

the number of long-term symptoms is reported in Figure 3.

Sensitivity analyses adjusting M1–6 for the COVID-19 severity or the time distance between

swab positivity and the baseline assessment (April 2020) confirmed all the significant effects

of sleep variables. Results were also confirmed using sleep outcomes collected in December

2020 as predictors of one-month symptoms (see Table S2 and Figure S2 in the supplemental

material).

Finally, supplementary analyses showed that the occurred variations in sleep quality, insomnia

severity, and sleep duration between April and December 2020 significantly predicted the

number of long-term symptoms one month after infection (see Table S3 and Figure S3 in the

13

supplemental material).

Table 2. Results from the negative binomial portion of the zero-inflated negative binomial regressions [exp(B), 95% confidence intervals, p-value] estimating the effect of sleep variables (PSQI score, ISI score, TST) and confounding factors (age, gender, BMI) in April 2020 on the number of long-term symptoms one month (M1, M2, M3) and three months after COVID-19 (M4, M5, M6).

Dradiator	M1: sleep quality			M2: insomnia severity			M3: sleep duration		
Predictor	exp(B)	95% CI	р	exp(B)	95% CI	р	exp(B)	95% CI	р
Intercept	2.325	1.461-3.699	< 0.001	2.315	1.465-3.658	< 0.001	9.182	4.494-18.761	< 0.001
Gender*	0.912	0.724-1.149	0.433	0.878	0.701-1.101	0.260	0.819	0.649-1.034	0.093
Age	0.990	0.983-0.998	0.009	0.992	0.984-0.999	0.030	0.987	0.979-0.995	0.001
BMI	1.023	1.006-1.041	0.008	1.024	1.006-1.041	0.008	1.026	1.008-1.045	0.004
PSQI score	1.070	1.046-1.094	< 0.001						
ISI score				1.049	1.033-1.064	< 0.001			
TST (hour)							0.889	0.840-0.941	< 0.001
	M4: sleep quality			M5: insomnia severity			M6: sleep duration		
Intercept	1.312	0.551-3.124	0.540	1.706	0.776-3.752	0.184	8.668	2.478-30.317	0.001
Gender*	1.021	0.592-1.446	0.733	1.017	0.644-1.550	0.997	1.027	0.522-1.278	0.375
Age	1.002	0.987-1.018	0.772	1.002	0.988-1.017	0.746	0.996	0.980-1.012	0.628
BMI	0.925	0.990-1.054	0.184	0.999	0.986-1.048	0.284	0.816	0.995-1.059	0.097
PSQI score	1.091	1.047-1.136	< 0.001						
ISI score				1.054	1.027-1.082	< 0.001			
TST (hour)							0.853	0.769-0.946	0.003

Notes: \*Female was used as reference for "Gender" factor; significant values are in bold. Abbreviations: BMI, Body mass index; CI, Confidence interval; ISI, Insomnia Severity Index; M, Model; PSQI, Pittsburgh Sleep Quality Index; TST, Total sleep time.




Figure 3. Relationships between sleep variables (PSQI score, ISI score, TST) in April 2020 and the number of long-term symptoms one month (M1, M2, M3) and three months after COVID-19 (M4, M5, M6).

Notes: Light blue area represents 95% confidence intervals. Each model was adjusted for age, gender, and body

Abbreviations: ISI, Insomnia Severity Index; M, Model; PSQI, Pittsburgh Sleep Quality Index; TST, Total sleep time.

Association between pre-infection sleep and each long-term symptom after

COVID-19

Results of binomial logistic regressions using sleep variables collected in April 2020 as

predictors indicated that higher PSQI scores significantly increased the odds of each analyzed

long-term symptom at one (Figure 4a) and three months from COVID-19 (Figure 4b), except

for smell/taste dysfunctions, and cardiovascular problems experienced at one month from

infection. More severe insomnia symptoms were significantly associated with higher odds of

all analyzed long-term symptoms, excluding smell/taste dysfunctions Figure 4c,d). Finally, a

one-hour decrease in sleep duration was associated with higher odds of all one-month long-

term symptoms, except for asthenia, memory problems, smell/taste dysfunctions, appetite

reduction, and cardiovascular problems (Figure 4e). Furthermore, reduced sleep duration was

associated with increased risk for all symptoms reported after 3 months from infection.

excluding over-tiredness, concentration/attention difficulty, anxiety, depression, and

smell/taste dysfunctions (Figure 4f).

Control analyses using Firth's bias-reduced logistic regressions produced almost identical

results to those obtained using the reported binomial logistic regressions, rejecting possible

bias due to the low number of events per predictor for some long-term symptoms. Similarly,

adjusting for self-reported COVID-19 severity or the time distance between SARS-CoV-2

infection and the baseline assessment (April 2020) confirmed the overall pattern of results.

Finally, logistic models using PSQI score, ISI score, and TST of December 2020 as predictors

of symptoms reported one month after COVID-19 partially confirmed the above-described

15

results (see Figure S4 in the supplemental material).




Figure 4. Results of logistic regressions (odd ratios and 95% confidence intervals) evaluating the predictive effect of sleep variables (PSQI score, ISI score, TST) in April 2020 on the odds of each longterm symptom one month (a, c, e) and three months after COVID-19 (b, d, f).

Notes: Long-term symptoms were ordered according to the prevalence data (top: most frequent) and represent the dependent variables. White dot indicates significance level at p < 0.05, grey dot at p < 0.01, and black dot at p < 0.050.001. "x" symbol indicates no statistically significant effect. Grey area indicates insufficient (< 5) outcome events per predictor. Each model was adjusted for age, gender, and body mass index.

Abbreviations: CI, Confidence Interval; ISI, Insomnia Severity Index; OCD, obsessive-compulsive disorder; OR, odd ratio; PSQI, Pittsburgh Sleep Quality Index; PTSD, post-traumatic stress disorder; TST, Total sleep time.

#### Association between pre-infection sleep and recovery time after COVID-19

Binomial logistic regression showed that poor sleep quality, more severe insomnia symptoms. and shorter sleep duration in April 2020 predicted longer recovery time to return to the preinfection daily functioning level after COVID-19 (Figure 5). A one-unit increase in PSQI and ISI scores, and a one-hour reduction of sleep duration were prospectively associated with higher odds of recovery in more than four weeks by 13.1%, 9.3%, and 14.4%, and after twelve weeks by 21.3%, 12.0%, and 20.2%, respectively. Adjusting for COVID-19 severity and the time distance between April 2020 assessment and the virus infection confirmed the above results. Finally, logistic regressions using sleep variables collected in December 2020 as predictors confirmed the significant association between recovery after 4 weeks with PSQI and ISI scores (see supplemental material).




Figure 5. Results of logistic regressions (odd ratios and 95% confidence intervals) evaluating the predictive effect of sleep variables (PSQI score, ISI score, TST) in April 2020 on the odds of returning to the pre-infection daily functioning level after 4 and 12 weeks.

Notes: Self-reported recovery after 4 and 12 weeks was evaluated on 713 and 333 subjects, respectively. White dot indicates significance level at p < 0.05, grey dot at p < 0.01, and black dot at p < 0.001. Each model was adjusted for age, gender, and body mass index.

Abbreviations: CI, Confidence Interval; ISI, Insomnia Severity Index; OR, Odd ratio; PSQI, Pittsburgh Sleep Quality Index; TST, Total sleep time.

**Discussion** 

Since the beginning of the pandemic, millions of people worldwide have reported signs and

symptoms that continue or develop after COVID-19, affecting their ability to resume normal

life and giving rise to serious public health concerns.8

To the best of our knowledge, this study is the first to find a prospective association between

pre-infection sleep disturbances and the occurrence of long-term symptoms after COVID-19.

We highlighted significant dose-dependent relationships between previous sleep quality,

insomnia severity, and sleep duration and the number of symptoms experienced at one and

three months from the reported positive swab for SARS-CoV-2. Moreover, our study showed

that lower sleep quality, more severe insomnia, and shorter sleep time lead to higher odds of

experiencing a broad spectrum of clinical manifestations one and three months after COVID-

19. Finally, we found that previous sleep problems are related to longer recovery times for

returning to the self-perceived pre-infection daily functioning.

Our results were consistent with a recent study on a sample of female nurses that found an

association between short sleep duration collected in 2017 and the occurrence of post-COVID-

19 conditions.44

Immune dysregulation and inflammatory mechanisms may explain the association between

sleep and subsequent post-COVID-19 manifestations. Consistent literature showed that sleep

disturbances are associated with heightened systemic inflammation, as evidenced by

increased levels of pro-inflammatory cytokines, 17,45-48 C-reactive protein, 17,47-50 and other

markers of inflammation. 46,51 This evidence has been proposed to explain the documented

higher risk for inflammatory diseases in people with sleep disturbances. <sup>17,18</sup> On the other hand,

findings from animal<sup>52,53</sup> and human models<sup>9–12</sup> suggested that a possible mechanism behind

the long COVID symptoms may involve an abnormal and persistent pro-inflammatory

response weeks/months after infection. For example, Phetsouphanh and collaborators<sup>9</sup>

compared immune profiles of long COVID individuals with patients without long COVID,

18

identifying a combination of inflammatory mediators eight months after infection as the correlate of persistent post-COVID-19 symptoms.

Another interpretation may involve the role of sleep loss as a driver of cellular stress and the consequent neuronal damage<sup>54</sup> in the cognitive and neuropsychiatric manifestations of long COVID.55

Finally, pre-pandemic evidence suggested that insufficient sleep could impair the vaccination efficacy, 56-58 and the importance of sleep health has also been advocated for the COVID-19 vaccination campaign. 59,60 Since previous COVID-19 vaccination seems to reduce the risk of long COVID,61 the link between sleep and post-COVID-19 symptoms may be mediated by the impact of sleep deficiency on the vaccination effectiveness. However, providing a clear understanding of the link between sleep and subsequent long-term symptoms after SARS-CoV-2 infection transcends the objectives and the capacity of the present investigation. Future studies should address this question to identify the potential underlying biobehavioral mechanisms of the sleep-long COVID relationship.

In a recent study, Wang and collaborators<sup>62</sup> showed that pre-infection psychological distress was prospectively associated with the incidence of various post-COVID-19 conditions. The similarity with our findings is unsurprising considering the close relationship between sleep disturbances and short sleep duration with psychological conditions like anxiety,63,64 depression, <sup>63,65–67</sup> and stress disorders. <sup>68,69</sup> Furthermore, a growing body of evidence supports a causal role of sleep problems in the occurrence of mental health problems, 65,70-72 and treating sleep disturbances seems to improve the subsequent mental health outcomes.<sup>73–75</sup> In this view, we could speculate that pre-infection sleep disturbances may get involved in the predictive role of psychological distress in the incidence of post-COVID-19 symptoms. In line with Wang and colleagues' study,62 smell/taste dysfunction represented the only long-term symptom not prospectively associated with all previous sleep outcomes. However, as argued by those authors, 62 the variability in anosmia incidence in long COVID may be explained by genetic or binding activity differences of the cell entry receptor for SARS-CoV-2 (the angiotensin-converting enzyme 2 receptor), <sup>76</sup> and may be independent from inflammatory

mechanisms potentially involved in the effects of distress and sleep. Further investigations should address this research question.

**Limitations and strengths** 

The present study has several strengths. The predictive effect of sleep variables was obtained by adjusting for important confounding factors (age, gender, and BMI) that were associated by previous studies with a higher risk for long COVID symptoms. 19-21 Furthermore, the main findings were confirmed after controlling for the COVID-19 severity, which is an established predictor of long COVID conditions, 2,19,20,27 but also a documented outcome of previous sleep problems.<sup>77,78</sup> Third, the results were replicated in the same sample by using a different baseline assessment in December 2020. Finally, our findings were confirmed after controlling for the time elapsed from the baseline sleep assessment to the infection, suggesting a predictive role of sleep features even after several months. Nevertheless, it is worth noting that also the changes in sleep quality/quantity over time could affect the post-COVID-19 sequelae. In fact, variations in sleep variables between April and December 2020 were associated with the subsequent number of symptoms one month after infection (see Table S3 and Figure S3 in the supplemental material).

Several limitations should also be acknowledged. Notwithstanding our results rely on a longitudinal data collection, the long-term symptoms after COVID-19 were retrospectively reported by participants during the last follow-up assessment (April 2022). Second, the lack of evaluation of potential pre-existing health conditions and behaviors did not allow our analyses to account for other risk factors for post-COVID-19 conditions (e.g., type 2 diabetes, asthma, smoking status, physical activity). Moreover, sleep quality, insomnia symptoms, and sleep duration were evaluated using validated self-report instruments. Future longitudinal investigations should confirm our results using objective sleep-assessment instruments (actigraphy, polysomnography) and/or a clinical evaluation of sleep disturbances. Finally, our

samples consisted of non-hospitalized adults and comprised a higher portion of female

subjects, limiting the generalization of the results.

**Conclusions** 

In conclusion, this study suggests that pre-existing sleep disturbances and inadequate sleep

duration are associated with subsequent risk of long-term symptoms after COVID-19. Our

findings could have large-scale implications considering the sleep-loss epidemic in our

society<sup>79,80</sup> and the considerable rates of insomnia disorder and occasionally experienced

insomnia symptoms among the adult population (10% and 20%, respectively).81 Furthermore,

the present results may be even more relevant during a historical period that pervasively

impacted the worldwide population's sleep. Indeed, meta-analytic studies showed that half of

the people experienced subthreshold and clinically significant insomnia symptoms in the first

two pandemic years, 82 and sleep disturbances affected four out of ten people worldwide.83

Raising public awareness about healthy sleep habits may represent an effective preventive

approach to mitigate the COVID-19 repercussions in the long run, with substantial indirect

effects at societal level. Further research is warranted to determine whether intervention aimed

at promoting sleep quality/quantity could improve the long-term consequences of COVID-19.

**Acknowledgments** 

We are grateful to all the Italians who participated in our study.

FS: Conceptualization, Methodology, Investigation, Data curation, Formal analysis, Writing -

original draft, Writing - review & editing. GA: Investigation. DC: Investigation. LV: Investigation.

ADA: Writing - review & editing. DT: Writing - review & editing. MF: Conceptualization,

21

Methodology, Investigation, Supervision, Writing - review & editing.

# **Disclosure statement**

Financial Disclosure: none.

Non-financial Disclosure: none

# Data availability statement

The data underlying this article will be shared on reasonable request to the corresponding author.

# References

- 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Published 2023. Accessed January 29, 2023. https://covid19.who.int
- 2. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022;226(9):1593-1607. doi:10.1093/INFDIS/JIAC136
- 3. O'Mahonev LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and metaanalysis. EClinicalMedicine. 2023;55:101762. doi:10.1016/j.eclinm.2022.101762
- Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 4. symptoms months of and their impact. EClinicalMedicine. 2021:38:101019. doi:10.1016/j.eclinm.2021.101019
- 5. Badenoch JB, Rengasamy ER, Watson C, et al. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. Brain Commun. 2021;4(1). doi:10.1093/BRAINCOMMS/FCAB297
- 6. O' Mahony L, Buwalda T, Blair M, et al. Impact of Long COVID on health and quality of life. HRB Open Res. 2022;5:31. doi:10.12688/HRBOPENRES.13516.1
- 7. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 symptoms impact. EClinicalMedicine. months of and their 2021;38. doi:10.1016/j.eclinm.2021.101019
- The Lancet. Understanding long COVID: a modern medical challenge. The Lancet. 8. 2021;398(10302):725. doi:10.1016/S0140-6736(21)01900-0
- Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months 9. following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022 23:2. 2022;23(2):210-216. doi:10.1038/s41590-021-01113-x
- 10. Mazza MG, Palladini M, de Lorenzo R, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun. 2021;94:138-147. doi:10.1016/J.BBI.2021.02.021
- 11. Mazza MG, de Lorenzo R, Conte C, et al. Anxiety and depression in COVID-19 survivors: Role inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594-600. doi:10.1016/J.BBI.2020.07.037
- 12. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors, and management. BMJ. 2021;374. doi:10.1136/BMJ.N1648
- 13. Besedovsky L, Lange T, Born J. Sleep and immune function. Pflugers Archiv. 2012;463(1):121. doi:10.1007/S00424-011-1044-0
- Bryant PA, Trinder J, Curtis N. Sick and tired: does sleep have a vital role in the immune system? 14. Nat Rev Immunol. 2004 4:6. 2004;4(6):457-467. doi:10.1038/nri1369
- Prather AA, Janicki-Deverts D, Hall MH, Cohen S. Behaviorally Assessed Sleep and 15. Susceptibility to the Common Cold. Sleep. 2015;38(9):1353-1359. doi:10.5665/SLEEP.4968
- 16. Cohen S, Doyle WJ, Alper CM, Janicki-Deverts D, Turner RB. Sleep habits and susceptibility to common cold. Arch Intern Med. 2009;169(1):62-67. doi:10.1001/ARCHINTERNMED.2008.505
- 17. Irwin MR, Olmstead R, Carroll JE. Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation. Biol Psychiatry. 2016;80(1):40-52. doi:10.1016/J.BIOPSYCH.2015.05.014
- Garbarino S, Lanteri P, Bragazzi NL, Magnavita N, Scoditti E. Role of sleep deprivation in 18. immune-related disease risk and outcomes. Commun Biol. 2021 4:1. 2021;4(1):1-17. doi:10.1038/s42003-021-02825-4
- 19. Huang Q, Jia M, Sun Y, et al. One-Year Temporal Changes in Long COVID Prevalence and Characteristics: A Systematic Review and Meta-Analysis. Value in Health. Published online November 24, 2022. doi:10.1016/J.JVAL.2022.11.011
- 20. Zeng N, Zhao YM, Yan W, et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry 2022 28:1. 2022;28(1):423-433. doi:10.1038/s41380-022-01614-7
- 21. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021 27:4. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y
- 22. Salfi F, Lauriola M, D'Atri A, et al. Demographic, psychological, chronobiological, and workrelated predictors of sleep disturbances during the COVID-19 lockdown in Italy. Sci Rep. 2021;11(1):1-12. doi:10.1038/s41598-021-90993-y

- 23. Salfi F, D'Atri A, Tempesta D, Ferrara M. Sleeping under the waves: A longitudinal study across the contagion peaks of the COVID-19 pandemic in Italy. J Sleep Res. 2021;30(5). doi:10.1111/jsr.13313
- 24. Salfi F, Amicucci G, Corigliano D, et al. Two years after lockdown: Longitudinal trajectories of sleep disturbances and mental health over the COVID-19 pandemic, and the effects of age, gender and chronotype. J Sleep Res. Published online 2022. doi:10.1111/JSR.13767
- 25. Curcio G, Tempesta D, Scarlata S, et al. Validity of the Italian Version of the Pittsburgh Sleep Quality Index (PSQI). Neurol Sci. 2013;34(4):511-519. doi:10.1007/s10072-012-1085-y
- 26. Castronovo V, Galbiati A, Marelli S, et al. Validation study of the Italian version of the Insomnia Severity Index (ISI). Neurol Sci. 2016;37(9):1517-1524. doi:10.1007/s10072-016-2620-z
- 27. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416-427. doi:10.1016/S2215-0366(21)00084-5
- 28. Gardner W. Mulvev EP. Shaw EC. Regression Analyses of Counts and Rates: Poisson. Overdispersed Poisson, and Negative Binomial Models. Psychol Bull. 1995;118(3):392-404. doi:10.1037/0033-2909.118.3.392
- 29. Coxe S, West SG, Aiken LS. The analysis of count data: a gentle introduction to poisson regression and its alternatives. J Pers Assess. 2009;91(2):121-136. doi:10.1080/00223890802634175
- 30. Payne EH, Gebregziabher M, Hardin JW, Ramakrishnan V, Egede LE. An empirical approach to determine a threshold for assessing overdispersion in Poisson and negative binomial models for count data. Commun Stat Simul Comput. 2018;47(6):1722. doi:10.1080/03610918.2017.1323223
- 31. Hilbe JM. Negative Binomial Regression. Negative Binomial Regression, Second Edition. Published online January 1, 2011:1-553. doi:10.1017/CBO9780511973420
- 32. Land KC, McCall PL, Nagin DS. A Comparison of Poisson, Negative Binomial, and Semiparametric Mixed Poisson Regression Models. Sociol Methods Res. 2016;24(4):387-442. doi:10.1177/0049124196024004001
- Moghimbeigi A, Eshraghian MR, Mohammad K, Mcardle B. Multilevel zero-inflated negative 33. binomial regression modeling for over-dispersed count data with extra zeros. J Appl Stat. 2008;35(10):1193-1202. doi:10.1080/02664760802273203
- 34. Cameron CA, Trivedi P. Regression analysis of count data, Second edition. Regression Analysis Count Data. Second Edition. Published online January doi:10.1017/CBO9781139013567
- Green JA. Too many zeros and/or highly skewed? A tutorial on modelling health behaviour as 35. count data with Poisson and negative binomial regression. Health Psychol Behav Med. 2021;9(1):436-455. doi:10.1080/21642850.2021.1920416
- Zeileis A, Kleiber C, Jackman S. Regression Models for Count Data in R. J Stat Softw. 36. 2008;27(8):1-25. doi:10.18637/JSS.V027.I08
- 37. Tukey JW. Exploratory Data Analysis. Addison-Wesley Publishing Company; 1977.
- Kleiber C, Zeileis A. Visualizing Count Data Regressions Using Rootograms. Am Stat. 38. 2016;70(3):296-303. doi:10.1080/00031305.2016.1173590
- 39. R Core Team. R: A language and environment for statistical computing. Published online 2022. https://www.r-project.org/
- 40. Vittinghoff E, McCulloch CE. Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression. Am J Epidemiol. 2007;165(6):710-718. doi:10.1093/AJE/KWK052
- 41. Heinze G, Puhr R. Bias-reduced and separation-proof conditional logistic regression with small or sparse data sets. Stat Med. 2010;29(7-8):770-777. doi:10.1002/SIM.3794
- 42. Heinze G, Ploner M, Dunkler D, Southworth H, Jiricka L. Package 'logistf.' Version 1.24.1. Published 2022. Accessed January 2023. https://cran.r-18, project.org/web/packages/logistf/logistf.pdf
- CDC Centers for disease control and prevention. Overweight & Obesity. Published 2023. 43. Accessed January 25, 2023. https://www.cdc.gov/obesity/basics/adult-defining.html
- 44. Wang S. Li Y. Yue Y. et al. Adherence to Healthy Lifestyle Prior to Infection and Risk of Post-COVID-19 Condition. JAMA Med. Published online February 6, Intern doi:10.1001/JAMAINTERNMED.2022.6555
- 45. Mills PJ, von Känel R, Norman D, Natarajan L, Ziegler MG, Dimsdale JE. Inflammation and Sleep in Healthy Individuals. Sleep. 2007;30(6):729-735. doi:10.1093/SLEEP/30.6.729

- 46. Nowakowski S, Matthews KA, von Känel R, Hall MH, Thurston RC. Sleep characteristics and inflammatory biomarkers among midlife women. Sleep. 2018;41(5). doi:10.1093/SLEEP/ZSY049
- 47. Cho HJ, Seeman TE, Kiefe CI, Lauderdale DS, Irwin MR. Sleep disturbance and longitudinal risk of inflammation: Moderating influences of social integration and social isolation in the Coronary Artery Risk Development in Young Adults (CARDIA) study. Brain Behav Immun. 2015;46:319-326. doi:10.1016/J.BBI.2015.02.023
- Ferrie JE, Kivimäki M, Akbaraly TN, et al. Associations Between Change in Sleep Duration and 48. Inflammation: Findings on C-reactive Protein and Interleukin 6 in the Whitehall II Study. Am J Epidemiol. 2013;178(6):956-961. doi:10.1093/AJE/KWT072
- 49. Liukkonen T, Räsänen P, Ruokonen A, et al. C-reactive protein levels and sleep disturbances: Observations based on the Northern Finland 1966 birth cohort study. Psychosom Med. 2007:69(8):756-761. doi:10.1097/PSY.0B013E318157CB96
- 50. Ghilotti F, Bellocco R, Trolle Lagerros Y, et al. Relationship between sleep characteristics and markers of inflammation in Swedish women from the general population. J Sleep Res. 2021;30(2):e13093. doi:10.1111/JSR.13093
- 51. Irwin MR, Wang M, Campomayor CO, Collado-Hidalgo A, Cole S. Sleep Deprivation and Activation of Morning Levels of Cellular and Genomic Markers of Inflammation. Arch Intern Med. 2006;166(16):1756-1762. doi:10.1001/ARCHINTE.166.16.1756
- Frere JJ, Serafini RA, Pryce KD, et al. SARS-CoV-2 infection in hamsters and humans results 52. in lasting and unique systemic perturbations after recovery. Sci Transl Med. 2022;14(664):3059. doi:10.1126/SCITRANSLMED.ABQ3059
- 53. Rutkai I, Mayer MG, Hellmers LM, et al. Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates. Nat Commun. 2022;13(1):1-13.doi:10.1038/s41467-022-29440-z
- 54. Coulson RL, Mourrain P, Wang GX. Sleep deficiency as a driver of cellular stress and damage in neurological disorders. Sleep Med Rev. 2022;63:101616. doi:10.1016/J.SMRV.2022.101616
- 55. Schilling C, Meyer-Lindenberg A, Schweiger JI. Cognitive disorders and sleep disturbances in long COVID. Nervenarzt. 2022;93(8):779-787. doi:10.1007/S00115-022-01297-Z
- Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. Clin 56. Microbiol Rev. 2019;32(2). doi:10.1128/CMR.00084-18
- 57. Spiegel K, Sheridan JF, van Cauter E. Effect of Sleep Deprivation on Response to Immunizaton. JAMA. 2002;288(12):1471-1472. doi:10.1001/JAMA.288.12.1469
- 58. Prather AA, Pressman SD, Miller GE, Cohen S. Temporal Links Between Self-Reported Sleep and Antibody Responses to the Influenza Vaccine. Int J Behav Med. 2021;28(1):151-158. doi:10.1007/S12529-020-09879-4
- Rayatdoost E, Rahmanian M, Sanie MS, et al. Sufficient Sleep, Time of Vaccination, and 59. Vaccine Efficacy: A Systematic Review of the Current Evidence and a Proposal for COVID-19 Vaccination. Yale J Biol Med. 2022;95(2):221.
- Benedict C, Cedernaes J. Could a good night's sleep improve COVID-19 vaccine efficacy? 60. Lancet Respir Med. 2021;9(5):447-448. doi:10.1016/S2213-2600(21)00126-0
- 61. Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022;53:101624. doi:10.1016/j.eclinm.2022.101624
- 62. Wang S, Quan L, Chavarro JE, et al. Associations of Depression, Anxiety, Worry, Perceived Stress, and Loneliness Prior to Infection With Risk of Post-COVID-19 Conditions. JAMA Psychiatry. 2022;79(11):1081-1091. doi:10.1001/JAMAPSYCHIATRY.2022.2640
- 63. Alvaro PK, Roberts RM, Harris JK. A Systematic Review Assessing Bidirectionality between Sleep Disturbances, Anxiety, and Depression. Sleep. 2013;36(7):1059-1068. doi:10.5665/SLEEP.2810
- 64. Cox RC, Olatunji BO. Sleep in the anxiety-related disorders: A meta-analysis of subjective and objective research. Sleep Med Rev. 2020;51:101282. doi:10.1016/J.SMRV.2020.101282
- Zhai L, Zhang H, Zhang D. Sleep duration and depression among adults: A meta-analysis of 65. prospective studies. Depress Anxiety. 2015;32(9):664-670. doi:10.1002/da.22386
- Watson NF, Harden KP, Buchwald D, et al. Sleep duration and depressive symptoms: A gene-66. environment interaction. Sleep. 2014;37(2):351-358. doi:10.5665/sleep.3412
- 67. Fang H, Tu S, Sheng J, Shao A. Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med. 2019;23(4):2324-2332. doi:10.1111/JCMM.14170

- 68. Zhang Y, Ren R, Sanford LD, et al. Sleep in posttraumatic stress disorder: A systematic review and meta-analysis of polysomnographic findings. Sleep Med Rev. 2019;48:101210. doi:10.1016/J.SMRV.2019.08.004
- 69. Gardani M. Bradford DRR. Russell K. et al. A systematic review and meta-analysis of poor sleep. insomnia symptoms and stress in undergraduate students. Sleep Med Rev. 2022;61:101565. doi:10.1016/J.SMRV.2021.101565
- 70. Hertenstein E, Feige B, Gmeiner T, et al. Insomnia as a predictor of mental disorders: A Med systematic review and meta-analysis. Sleep Rev. 2019;43:96-105. doi:10.1016/j.smrv.2018.10.006
- Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: A meta-analytic 71. evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135(1-3):10-19. doi:10.1016/J.JAD.2011.01.011
- 72. Pigeon WR, Bishop TM, Krueger KM, Insomnia as a Precipitating Factor in New Onset Mental Illness: a Systematic Review of Recent Findings. Curr Psychiatry Rep. 2017;19(8). doi:10.1007/S11920-017-0802-X
- Scott AJ, Webb TL, Martyn-St James M, Rowse G, Weich S. Improving sleep quality leads to 73. better mental health: A meta-analysis of randomised controlled trials. Sleep Med Rev. 2021;60:101556. doi:10.1016/J.SMRV.2021.101556
- 74. Ho FYY, Chan CS, Tang KNS. Cognitive-behavioral therapy for sleep disturbances in treating posttraumatic stress disorder symptoms: A meta-analysis of randomized controlled trials. Clin Psychol Rev. 2016;43:90-102. doi:10.1016/J.CPR.2015.09.005
- 75. Freeman D, Sheaves B, Goodwin GM, et al. The effects of improving sleep on mental health (OASIS): a randomised controlled trial with mediation analysis. Lancet Psychiatry. 2017;4(10):749-758. doi:10.1016/S2215-0366(17)30328-0
- 76. Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and Assessment of Olfactory Route to Brain Infection. Neuroscientist. 2021;27(6):582-603. doi:10.1177/1073858420956905
- Huang B, Niu Y, Zhao W, Bao P, Li D. Reduced sleep in the week prior to diagnosis of COVID-77. 19 is associated with the severity of COVID-19. Nat Sci Sleep. 2020;12:999-1007. doi:10.2147/NSS.S263488
- 78. Jones SE, Maisha FI, Strausz S, et al. Public health impact of poor sleep on COVID-19, influenza respiratory infections. Sleep Med. 2022;100:S135. doi:10.1016/J.SLEEP.2022.05.369
- 79. Wang S. Rossheim ME. Nandy RR. Trends in prevalence of short sleep duration and trouble sleeping among US adults, 2005-2018. Sleep. 2023;46(1). doi:10.1093/SLEEP/ZSAC231
- 80. Chattu VK, Manzar MD, Kumary S, Burman D, Spence DW, Pandi-Perumal SR. The Global Problem of Insufficient Sleep and Its Serious Public Health Implications. Healthcare (Basel). 2018;7(1). doi:10.3390/HEALTHCARE7010001
- Morin CM, Jarrin DC. Epidemiology of Insomnia: Prevalence, Course, Risk Factors, and Public 81. Health Burden. Sleep Med Clin. 2022;17(2):173-191. doi:10.1016/J.JSMC.2022.03.003
- AlRasheed MM, Fekih-Romdhane F, Jahrami H, et al. The prevalence and severity of insomnia 82. symptoms during COVID-19: A global systematic review and individual participant data metaanalysis. Sleep Med. 2022;100:7-23. doi:10.1016/J.SLEEP.2022.06.020
- 83. Jahrami H, Alhaj OA, Humood AM, et al. Sleep disturbances during the COVID-19 pandemic: A systematic review, meta-analysis, and meta-regression. Sleep Med Rev. 2022;62:101591. doi:10.1016/j.smrv.2022.101591